Policy Analysis of The Texas Compassionate Use Program

Area of Science:

• Medical Cannabis Policy
• Public Health
• Renal Disease Management

Background:

• Established in 2015, the Texas Compassionate Use Program provides regulated access to low-THC cannabis for specific medical conditions.
• Despite legislative expansions, it remains a highly restrictive medical cannabis program in the U.S.

Purpose of the Study:

• Evaluate the effectiveness and public health impact of the Texas Compassionate Use Program.
• Focus on patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) on dialysis, who often experience significant symptom burden.

Main Methods:

• Policy analysis of the Texas Compassionate Use Program.
• Review of existing evidence on medical cannabis for symptom management in CKD/ESRD patients.
• Examination of policy gaps, clinical considerations, and substance use implications.

Main Results:

• Medical cannabis shows potential for improving quality of life and reducing opioid use.
• Barriers include limited clinical guidance, restrictive THC limits, and exclusion of dialysis patients.
• Policy gaps hinder effective implementation and patient access.

Conclusions:

• Recommendations include expanding qualifying conditions and enhancing provider education.
• Increasing patient access and integrating harm reduction strategies are crucial.
• Program refinement can improve outcomes for vulnerable populations while ensuring safety.